Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “Minor Discrepancies” between Marketing Approval and Actual Manufacturing Processes Found for about 70% of Products: MHLW
June 3, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Tax Hike Delay Kills Feared Price Cuts in 2017, but Concerns Linger over Expensive Drug Debate
June 2, 2016
- MHLW Proposes Discontinuing Supply of Human Thrombin Products
June 2, 2016
- MHLW Expects Stable Supply of Kaketsuken’s Blood Products Despite Earthquake Damage: Official
June 2, 2016
- Bisphosphonate Labels to Add Osteonecrosis of External Auditory Canal in ADR List
June 1, 2016
- Boehringer’s Reversal Agent for Pradaxa Becomes 1st Drug Subject to Japan’s Compassionate Use Scheme
June 1, 2016
- MHLW Initiates Discussions on Palliative Care for CV Diseases
June 1, 2016
- MHLW Drug Review Panel Shelves ASKA’s Hepatic Encephalopathy Drug
May 31, 2016
- Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
- AMED to Support Drug Discovery Research Using Existing Drugs as “Tool Compounds”
May 31, 2016
- G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
- MHLW Panel OKs Sanofi’s PCSK9 Inhibitor on Equal Footing with Repatha
May 30, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
- Pemphigoid Added to List of Clinically Significant Adverse Reactions for DPP-4 Inhibitors: Safety Bulletin
May 26, 2016
- MHLW Working Group Urges Govt to Push NTD Drug Development at Mie Summit
May 25, 2016
- MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…